Flexion Therapeutics, Inc. (FLXN): Price and Financial Metrics

Flexion Therapeutics, Inc. (FLXN)

Today's Latest Price: $11.51 USD

0.33 (-2.79%)

Updated Jan 21 1:02pm

Add FLXN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

FLXN Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for FLXN is -26.78 -- better than only 0.81% of US stocks.
  • FLXN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 1.26% of US stocks.
  • As for revenue growth, note that FLXN's revenue has grown 40.87% over the past 12 months; that beats the revenue growth of 87.89% of US companies in our set.
  • Stocks that are quantitatively similar to FLXN, based on their financial statements, market capitalization, and price volatility, are INSG, NLST, BNFT, ICPT, and ALIM.
  • Visit FLXN's SEC page to see the company's official filings. To visit the company's web site, go to www.flexiontherapeutics.com.

FLXN Stock Price Chart Interactive Chart >

Price chart for FLXN

FLXN Price/Volume Stats

Current price $11.51 52-week high $18.87
Prev. close $11.84 52-week low $5.01
Day low $11.33 Volume 318,680
Day high $12.04 Avg. volume 558,382
50-day MA $11.62 Dividend yield N/A
200-day MA $11.55 Market Cap 567.62M

Flexion Therapeutics, Inc. (FLXN) Company Bio

Flexion Therapeutics focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The company was founded in 2007 and is based in Burlington, Massachusetts.

FLXN Latest News Stream

Event/Time News Detail
Loading, please wait...

FLXN Latest Social Stream

Loading social stream, please wait...

View Full FLXN Social Stream

Latest FLXN News From Around the Web

Below are the latest news stories about Flexion Therapeutics Inc that investors may wish to consider to help them evaluate FLXN as an investment opportunity.

Flexion Therapeutics: Fighting Through COVID-19 Headwinds

Flexion Therapeutics (FLXN) recently publicized their Q4 and full-year numbers that revealed the company expects to report full-year 2020 ZILRETTA net sales of about $85.5M. Admittedly, I wasn’t expecting the company to record growth in the middle of the pandemic, but they were able to battle the COVID-19 headwinds and...

Biologics on Seeking Alpha | January 17, 2021

Flexion Therapeutics anticipates Q4 Zilretta sales of $26.3M

Flexion Therapeutics ([[FLXN]] -2.5%) has issued guidance for Q4 2020 and sees Zilretta sales of ~26.3M, slightly higher than consensus estimate of $25.7. For FY2020, expects net sales of ~$85.5M."As a result of specialty distributor purchases in response to growing customer demand and a modest distributor buy-in at a small discount, the...

Seeking Alpha | January 13, 2021

Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference

BURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and…

GlobeNewswire | January 7, 2021

When Will Flexion Therapeutics, Inc. (NASDAQ:FLXN) Turn A Profit?

We feel now is a pretty good time to analyse Flexion Therapeutics, Inc.'s ( NASDAQ:FLXN ) business as it appears the...

Yahoo | December 21, 2020

Is FLXN A Good Stock To Buy Now?

In this article you are going to find out whether hedge funds think Flexion Therapeutics Inc (NASDAQ:FLXN) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]

Yahoo | December 16, 2020

Read More 'FLXN' Stories Here

FLXN Price Returns

1-mo -4.16%
3-mo -5.50%
6-mo -7.10%
1-year -37.48%
3-year -50.58%
5-year -26.69%
YTD -0.26%
2020 -44.25%
2019 82.86%
2018 -54.79%
2017 31.65%
2016 -1.30%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.028 seconds.